JP2024515618A5 - - Google Patents
Info
- Publication number
- JP2024515618A5 JP2024515618A5 JP2023562813A JP2023562813A JP2024515618A5 JP 2024515618 A5 JP2024515618 A5 JP 2024515618A5 JP 2023562813 A JP2023562813 A JP 2023562813A JP 2023562813 A JP2023562813 A JP 2023562813A JP 2024515618 A5 JP2024515618 A5 JP 2024515618A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110404963.8 | 2021-04-14 | ||
| CN202110404963 | 2021-04-14 | ||
| PCT/CN2022/086870 WO2022218383A1 (zh) | 2021-04-14 | 2022-04-14 | 抗体在抗肿瘤治疗中的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515618A JP2024515618A (ja) | 2024-04-10 |
| JP2024515618A5 true JP2024515618A5 (OSRAM) | 2025-04-22 |
Family
ID=83574345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562813A Pending JP2024515618A (ja) | 2021-04-14 | 2022-04-14 | 抗腫瘍処置における抗体の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240199741A1 (OSRAM) |
| EP (1) | EP4324854A4 (OSRAM) |
| JP (1) | JP2024515618A (OSRAM) |
| KR (1) | KR20230171456A (OSRAM) |
| CN (2) | CN120346314A (OSRAM) |
| AU (1) | AU2022258365A1 (OSRAM) |
| BR (1) | BR112023021177A2 (OSRAM) |
| CA (1) | CA3213734A1 (OSRAM) |
| IL (1) | IL307494A (OSRAM) |
| MX (1) | MX2023012182A (OSRAM) |
| PH (1) | PH12023552750A1 (OSRAM) |
| WO (1) | WO2022218383A1 (OSRAM) |
| ZA (1) | ZA202309812B (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220062503A (ko) * | 2019-08-02 | 2022-05-17 | 씨티티큐-아케소 (상하이) 바이오메드. 테크. 컴퍼니, 리미티드 | 항-pd-1 항체 및 이의 약제학적 용도 |
| CN115845050A (zh) * | 2022-12-28 | 2023-03-28 | 广州誉衡生物科技有限公司 | 抗-pd-1抗体及其在制备治疗食管鳞癌患者的药物中的用途 |
| AU2024232344A1 (en) * | 2023-03-07 | 2025-10-02 | Akeso Pharma Co., Ltd. | Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and use thereof |
| CN118562008B (zh) * | 2024-05-15 | 2025-06-03 | 复旦大学 | 一种靶向her2的纳米单克隆抗体及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104974253A (zh) * | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗ctla-4/pd-1双特异性抗体、其制备方法及应用 |
| CN106188296B (zh) * | 2016-07-19 | 2018-05-08 | 康融东方（广东）医药有限公司 | 一类抗血管内皮生长因子受体vegfr2的单克隆抗体及其编码基因和应用 |
| CN106967172B (zh) * | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| CN110505882A (zh) * | 2017-03-31 | 2019-11-26 | 默沙东公司 | 用pd-1的拮抗剂和抗ctla4抗体的组合治疗癌症的组合物和方法 |
| JP2021507706A (ja) * | 2017-12-21 | 2021-02-25 | アムニクス ファーマシューティカルズ， インコーポレイテッド | 放出セグメントおよびそれを含む結合組成物 |
| WO2019179421A1 (en) * | 2018-03-19 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/ctla-4 antibody molecules |
| CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| MX2021010997A (es) * | 2019-03-13 | 2021-10-01 | Merck Sharp & Dohme Llc | Terapias anticancerigenas combinadas que comprenden agentes bloqueadores ctla-4 y pd-1. |
| CN112300286A (zh) * | 2019-08-02 | 2021-02-02 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体及其用途 |
-
2022
- 2022-04-14 MX MX2023012182A patent/MX2023012182A/es unknown
- 2022-04-14 JP JP2023562813A patent/JP2024515618A/ja active Pending
- 2022-04-14 US US18/286,755 patent/US20240199741A1/en active Pending
- 2022-04-14 KR KR1020237038950A patent/KR20230171456A/ko active Pending
- 2022-04-14 WO PCT/CN2022/086870 patent/WO2022218383A1/zh not_active Ceased
- 2022-04-14 CA CA3213734A patent/CA3213734A1/en active Pending
- 2022-04-14 AU AU2022258365A patent/AU2022258365A1/en active Pending
- 2022-04-14 CN CN202510718166.5A patent/CN120346314A/zh active Pending
- 2022-04-14 CN CN202210401367.9A patent/CN115197325A/zh active Pending
- 2022-04-14 BR BR112023021177A patent/BR112023021177A2/pt unknown
- 2022-04-14 IL IL307494A patent/IL307494A/en unknown
- 2022-04-14 EP EP22787605.9A patent/EP4324854A4/en active Pending
- 2022-04-14 PH PH1/2023/552750A patent/PH12023552750A1/en unknown
-
2023
- 2023-10-20 ZA ZA2023/09812A patent/ZA202309812B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023504003A5 (OSRAM) | ||
| JP2025102836A5 (OSRAM) | ||
| IL293241A (en) | Bispecific antibody, anti-1-pd, anti-vegfa, pharmaceutical preparation containing it and its use | |
| JP2024509018A5 (OSRAM) | ||
| JP2024515396A5 (OSRAM) | ||
| JP2022542450A5 (OSRAM) | ||
| CN113302207B (zh) | Cd38和icam1抗体及其用途 | |
| JP2021515559A5 (OSRAM) | ||
| CN114181310B (zh) | 抗tigit抗体、其药物组合物及用途 | |
| JP2018534933A5 (OSRAM) | ||
| JP2020534351A5 (OSRAM) | ||
| JP2017522871A5 (OSRAM) | ||
| JP2025506318A5 (OSRAM) | ||
| JP2018520991A5 (OSRAM) | ||
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| JP2022525071A5 (OSRAM) | ||
| JP2024538669A5 (OSRAM) | ||
| US20240199741A1 (en) | Use of antibody in anti-tumor treatment | |
| JP2019512262A5 (OSRAM) | ||
| JP2024525916A5 (OSRAM) | ||
| JP2025520232A5 (OSRAM) | ||
| JP2025504496A5 (OSRAM) | ||
| JP2023506158A5 (OSRAM) | ||
| JP2023532852A5 (OSRAM) | ||
| RU2024125768A (ru) | Фармацевтическая композиция, содержащая биспецифическое антитело против ctla4-против pd-1 и чиаураниб |